Cargando…
肺鳞癌分子靶向治疗的研究现状
Lung cancer is one of the world's highest morbidity and mortality disease in malignant tumors currently.Squamous-cell lung cancer (SQCLC) is one of the most prevalent subtypes of lung cancer worldwide, after surgery, radiotherapy, chemotherapy and other comprehensive treatment, its 5-year survi...
Formato: | Online Artículo Texto |
---|---|
Lenguaje: | English |
Publicado: |
中国肺癌杂志编辑部
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6000367/ https://www.ncbi.nlm.nih.gov/pubmed/25130969 http://dx.doi.org/10.3779/j.issn.1009-3419.2014.08.07 |
_version_ | 1783331699662258176 |
---|---|
collection | PubMed |
description | Lung cancer is one of the world's highest morbidity and mortality disease in malignant tumors currently.Squamous-cell lung cancer (SQCLC) is one of the most prevalent subtypes of lung cancer worldwide, after surgery, radiotherapy, chemotherapy and other comprehensive treatment, its 5-year survival rate is still below 15%.The current molecular targeted therapy plays an important role in the treatment of SQCLC, an urgent need to be more in-depth study.SQCLC molecular targeted therapy mainly epidermal growth factor receptor (EGFR), phosphoin-3-kinase catalytic alpha polypeptide (PIK3CA), fibroblast growth factor receptor 1 (FGFR1), discoidin domain receptor 2 (DDR2), phosphatase and tensin homolog deleted on chromosome ten (PTEN), BRAF, MET, insulin-like growth factor 1 receptor (IGF-1R) and other as the target of the drug, some targeted drugs are being developed, and some targeted drugs have entered clinical trials.In recent years, with studies molecular targeted therapy in SQCLC, analysis of the development and trgeted therapy achieved substantial progress in improving the survival rate of SQCLC, and other research to improve the quality of life, make is possible to individualized targeted therapy of SQCLC. |
format | Online Article Text |
id | pubmed-6000367 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2014 |
publisher | 中国肺癌杂志编辑部 |
record_format | MEDLINE/PubMed |
spelling | pubmed-60003672018-07-06 肺鳞癌分子靶向治疗的研究现状 Zhongguo Fei Ai Za Zhi 综述 Lung cancer is one of the world's highest morbidity and mortality disease in malignant tumors currently.Squamous-cell lung cancer (SQCLC) is one of the most prevalent subtypes of lung cancer worldwide, after surgery, radiotherapy, chemotherapy and other comprehensive treatment, its 5-year survival rate is still below 15%.The current molecular targeted therapy plays an important role in the treatment of SQCLC, an urgent need to be more in-depth study.SQCLC molecular targeted therapy mainly epidermal growth factor receptor (EGFR), phosphoin-3-kinase catalytic alpha polypeptide (PIK3CA), fibroblast growth factor receptor 1 (FGFR1), discoidin domain receptor 2 (DDR2), phosphatase and tensin homolog deleted on chromosome ten (PTEN), BRAF, MET, insulin-like growth factor 1 receptor (IGF-1R) and other as the target of the drug, some targeted drugs are being developed, and some targeted drugs have entered clinical trials.In recent years, with studies molecular targeted therapy in SQCLC, analysis of the development and trgeted therapy achieved substantial progress in improving the survival rate of SQCLC, and other research to improve the quality of life, make is possible to individualized targeted therapy of SQCLC. 中国肺癌杂志编辑部 2014-08-20 /pmc/articles/PMC6000367/ /pubmed/25130969 http://dx.doi.org/10.3779/j.issn.1009-3419.2014.08.07 Text en 版权所有©《中国肺癌杂志》编辑部2014 https://creativecommons.org/licenses/by/3.0/ This is an open access article distributed in accordance with the terms of the Creative Commons Attribution (CC BY 3.0) License. See: https://creativecommons.org/licenses/by/3.0/ |
spellingShingle | 综述 肺鳞癌分子靶向治疗的研究现状 |
title | 肺鳞癌分子靶向治疗的研究现状 |
title_full | 肺鳞癌分子靶向治疗的研究现状 |
title_fullStr | 肺鳞癌分子靶向治疗的研究现状 |
title_full_unstemmed | 肺鳞癌分子靶向治疗的研究现状 |
title_short | 肺鳞癌分子靶向治疗的研究现状 |
title_sort | 肺鳞癌分子靶向治疗的研究现状 |
topic | 综述 |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6000367/ https://www.ncbi.nlm.nih.gov/pubmed/25130969 http://dx.doi.org/10.3779/j.issn.1009-3419.2014.08.07 |
work_keys_str_mv | AT fèilínáifēnzibǎxiàngzhìliáodeyánjiūxiànzhuàng AT fèilínáifēnzibǎxiàngzhìliáodeyánjiūxiànzhuàng AT fèilínáifēnzibǎxiàngzhìliáodeyánjiūxiànzhuàng |